Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP315011.RA4cxEy7md-cHB6PNB1BHZHxFbrI02zhok93Z7Jiq8D6k130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP315011.RA4cxEy7md-cHB6PNB1BHZHxFbrI02zhok93Z7Jiq8D6k130_provenance.
• NP472378.RA8i5sx0diWzdoQPIvyBGor4XBPs1fazruJDXsNjIsrIg130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP472378.RA8i5sx0diWzdoQPIvyBGor4XBPs1fazruJDXsNjIsrIg130_provenance.
• NP780409.RAStscnqjsNjD_oXQgq7GzGhkyemiU_H6wcpUB6nIiYog130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP780409.RAStscnqjsNjD_oXQgq7GzGhkyemiU_H6wcpUB6nIiYog130_provenance.
• assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP881167.RARu5siOj79wi_p5hPkhEu-IZudSvyOYFlqp_GUI00AuM130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881167.RARu5siOj79wi_p5hPkhEu-IZudSvyOYFlqp_GUI00AuM130_provenance.
• NP881170.RAU6SDFaOkebD-ZGscsppSENrcHXA4kfSr7oFuCKS1nfk130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881170.RAU6SDFaOkebD-ZGscsppSENrcHXA4kfSr7oFuCKS1nfk130_provenance.
• NP881162.RACFq7BAjOxvrhZqWa0pxe3zz-0YdUBO3Wp462HeV0bn4130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881162.RACFq7BAjOxvrhZqWa0pxe3zz-0YdUBO3Wp462HeV0bn4130_provenance.
• NP881166.RAqxGK1F3SkG5NVZI_zkoHUA91FpO02KQFhQffccQAKbI130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881166.RAqxGK1F3SkG5NVZI_zkoHUA91FpO02KQFhQffccQAKbI130_provenance.
• NP881171.RAKrmkIcVeU283WzWyQC2gDW4SoXIeRfaqv2OfIVEKnvk130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881171.RAKrmkIcVeU283WzWyQC2gDW4SoXIeRfaqv2OfIVEKnvk130_provenance.
• NP881161.RA8ixH7UVosQPkEYdvSziKnBfnsyQ8GzH53BqfrCFGYLc130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881161.RA8ixH7UVosQPkEYdvSziKnBfnsyQ8GzH53BqfrCFGYLc130_provenance.
• NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881163.RAz-bd16iP-SIKYltGFVNsfOBMAr1kSwgS3qnedM_XdVA130_provenance.
• NP881164.RA59WqZN2JAs8XM03OHehywEOYNZDJgKDERfV8Hx60lwg130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881164.RA59WqZN2JAs8XM03OHehywEOYNZDJgKDERfV8Hx60lwg130_provenance.
• NP881165.RA4_EMvQ9cDkWoQ_eEJnSqS8MxL-pHCBSWRsYoD_vPYvY130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881165.RA4_EMvQ9cDkWoQ_eEJnSqS8MxL-pHCBSWRsYoD_vPYvY130_provenance.
• NP881169.RA7f--A2VS68pT4LufIyV4kxQfMEUKnYWp_XJmlBCtZ6E130_assertion description "[Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881169.RA7f--A2VS68pT4LufIyV4kxQfMEUKnYWp_XJmlBCtZ6E130_provenance.